Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Mereo BioPharma Group plc is set to present at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its focus on rare diseases and ongoing clinical developments [1]. Company Overview - Mereo BioPharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases [3]. - The company has two primary product candidates: setrusumab for osteogenesis imperfecta (OI) and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) [3]. - Mereo has partnered with Ultragenyx Pharmaceutical, which has completed enrollment in the Phase 3 portion of a pivotal Phase 2/3 study for setrusumab in pediatric and young adult patients [3]. - The partnership includes potential milestone payments of up to $245 million and royalties on commercial sales in Ultragenyx territories, while Mereo retains EU and UK commercial rights [3]. - Setrusumab has received multiple designations from regulatory bodies, including orphan designation from the EMA and FDA, and Breakthrough Therapy designation from the FDA [3]. - Alvelestat has also received U.S. Orphan Drug Designation and Fast Track designation from the FDA [3]. Clinical Development - Mereo has aligned with the FDA and EMA on primary endpoints for a Phase 3 pivotal study for alvelestat, which could lead to full approval in both the U.S. and Europe if successful [3]. - In addition to rare disease programs, Mereo is developing two oncology product candidates: etigilimab and navicixizumab, with navicixizumab partnered with Feng Biosciences Inc. [3]. - Mereo has entered into a global license agreement with ReproNovo SA for the development of leflutrozole, a non-steroidal aromatase inhibitor [3].